SCM
ZVRA icon

Segantii Capital Management’s Zevra Therapeutics ZVRA Stock Holding History

Segantii Capital Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1,006
Closed -$241K – 123
2016
Q1 		$241K Buy
+1,006
New +$244K 0.1% 61

Other funds holding ZVRA

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
AWA
Arete Wealth Advisors Chicago, Illinois $1.51B AUM 33.02% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Segantii Capital Management's ZVRA Position: Q2 2016 in Review

Segantii Capital Management sold out of Zevra Therapeutics (ZVRA) in Q2 2016, closing a stake of 1,006 shares — an estimated $241K sold.

Segantii Capital Management first reported a position in ZVRA in Q1 2016 and held it in 1 quarter. The position peaked at $241K in Q1 2016. 40 funds tracked by Wall St. Rank hold ZVRA as of Q2 2016.

  • Segantii Capital Management reported no remaining Zevra Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Segantii Capital Management sold 1,006 Zevra Therapeutics shares in Q2 2016, an estimated $241K.
  • Segantii Capital Management first reported a position in Zevra Therapeutics in Q1 2016 and held it in 1 quarter.
  • Segantii Capital Management's Zevra Therapeutics position peaked at $241K in Q1 2016.
  • 40 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2016.

Based on Segantii Capital Management's 13F filing for Q2 2016, filed 15 Aug 2016.